News

New biologic on the horizon

Izana Bioscience, a new UK based pharmaceutical company, is running a phase 2 clinical trial for 42 patients across 10 centres in the UK for its new drug,  Namilumab.

Should you get a flu jab this winter?

Flu can be more severe in certain people, including anyone aged 65 and over and people with weakened immune systems. This would include people on biologic therapies like anti TNF or anti IL 17A, on regular steroids or taking DMARDs such as methotrexate

Britain leaving European Union

A no-deal Brexit?

NASS has been asked a few times recently about a no-deal Brexit and the impact that this may have on the supply of medicines to the UK.

NICE logo

NICE launch Quality Standard for Spondyloarthritis

NASS welcomes the publication today by NICE of a set of Quality Standards for Spondyloarthritis. Now we need to ensure that they are implemented effectively across the country so that every AS patient, every time, gets early diagnosis and high quality care.

Scan of Poppy's article

Poppy’s story

Many thanks to NASS Trustee Poppy, who has helped to raise awareness of the terrible impact living with AS can have on people's lives by sharing her family's story with Choice Magazine.